DOACs and Drug Interactions in Transplant Patients – JTH
Journal of Thrombosis and Haemostasis shared a post on LinkedIn about a recent article by Andreas Verstraete et al., adding:
“Direct oral anticoagulant use and drug-drug interactions in transplant recipients receiving calcineurin inhibitors.
Cyclosporine and tacrolimus inhibit the CYP3A4 and P-glycoprotein pathways that clear DOACs, raising concern about elevated drug levels.
Among 216 transplant recipients with 360 DOAC measurements, 11% were above-range, more often with rivaroxaban (20%) and apixaban (18%) than edoxaban (4%).
Higher levels tracked with strong CYP3A4 or P-glycoprotein inhibitors, lower weight, reduced kidney function, and cyclosporine use.”
Title: Direct oral anticoagulant use and drug-drug interactions in transplant recipients receiving calcineurin inhibitors
Authors: Andreas Verstraete, Erwin Dreesen, Quentin Van Thillo, Margot Erard, Dirk R.J. Kuypers, Marc Jacquemin, Filip Rega, Johan Van Cleemput, Jef Verbeek, Robin Vos, Peter Verhamme, Lorenz Van der Linden, Thomas Vanassche
Other posts about Journal of Thrombosis and Haemostasis on Hemostasis Today.
-
Oct 7, 2026, 16:44Amor Salah: 2026 NCS/SCCM Guidelines for Managing Antithrombotic-Associated ICH
-
Oct 7, 2026, 16:04NETs in Thrombosis: From Mechanism to Therapeutic Target
-
Oct 7, 2026, 15:28Amir Samimi: Prognostic Value of Platelet Count in Resected HNSCC
-
Oct 7, 2026, 15:21Eloïse Laouenan: Bridging Immunity and Thrombosis in MVTE
-
Oct 7, 2026, 15:10Uthra Sundaram: Honouring Donors During International Plasma Awareness Week
-
Oct 7, 2026, 15:04Daniel Victor Ortigoza: Should Frail Older Patients With AF Switch From VKA to DOACs?
-
Oct 7, 2026, 14:53Susan Noone: Donor Turned Recipient Shares Lifesaving Transfusion Story
-
Oct 7, 2026, 14:49Aimee Burtenshaw: The Impact of the Infected Blood Inquiry on Hospital Transfusion Laboratories
-
Oct 7, 2026, 14:41Vikash Jaiswal: Does Timing Matter for Calcium in Pre-Eclampsia Prevention?